|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, CX3CL1-Fc administration reduced diet-induced atherosclerosis after switching from an atherogenic to a normal chow diet.
|
30553772 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies disrupting the chemokine pathway CX3CL1 (fractalkine)/ CX3CR1 have shown decreased atherosclerosis in animal models but the techniques used to interrupt the pathway have not been easily translatable into human trials.
|
29641559 |
2018 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The 'M3' chemokine binding protein inactivates key chemokines involved in atherosclerosis (e.g.CCL2, CCL5 and CX3CL1).
|
28282403 |
2017 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The chemokine fractalkine (CX3C chemokine ligand 1; CX3CL1) and its receptor CX3CR1 are involved in the pathogenesis of several diseases, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, rheumatoid arthritis, hepatitis, myositis, multiple sclerosis, renal ischemia, and atherosclerosis.
|
28842393 |
2017 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Surprisingly, some markers of atherosclerosis (fractalkine/CX3CL1, CCL8, M-CSF, HGF), T-cell development/activation (CD40L, IL-7, CCL25, IL-2RB, IL-15RA, CD6) and angiogenesis (VEGF-A) were significantly increased only in AD.
|
28821884 |
2017 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CX3CL1/CX3CR1 expression was correlated with the severity of the atherosclerosis lesion.
|
25845619 |
2015 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further studies on the CX3CL1/CX3CR1 chemokine pathway are clearly warranted to justify the clinical relevance of its role in atherosclerosis.
|
23974513 |
2013 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fractalkine (CX3CL1) and its receptor (CX3CR1) comprise a chemokine system involved in leukocyte recruitment and adhesion in atherosclerosis, but its role in adipose inflammation and type 2 diabetes is unknown.
|
21525510 |
2011 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fractalkine (CX3CL1) is a membrane-bound chemokine that signals through the G protein-coupled receptor CX3CR1 that is implicated in the development of atherosclerosis.
|
19840952 |
2010 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings support the hypothesis that CX3CR1 and CX3CL1 mediate heterotypic anchorage of foam cells to CASMCs in the context of atherosclerosis and suggest that this chemokine/chemokine receptor pair may be considered as a pro-inflammatory target for therapeutic intervention in atherosclerotic cardiovascular disease.
|
17456471 |
2007 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
LHGDN |
Fractalkine in vascular biology: from basic research to clinical disease.
|
12969992 |
2004 |